Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

NCT04766398 | Completed Phase 3

• 1 other identifier: 7791-005
• Study Type: interventional
• Target: 169
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in combination with phosphate binders for 6 weeks and those receiving placebo in combination with phosphate binders.

Conditions

Hyperphosphatemia

Keywords

Tenapanor; Hyperphosphatemia; Hemodialysis

Outcome Measures

Primary Outcomes (1)

• Changes in serum phosphorous levels from baseline values at 8 weeks after the start of administration.

  Week 8

Secondary Outcomes (7)

• Changes in serum phosphorous levels from baseline values at each time point.

  Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

• Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 6.0).

  Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

• Time when the target serum phosphorus level (serum phosphorus level: ≤ 6.0) was achieved.

  Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

• Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 5.5).

  Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

• Time when the target serum phosphorus level (serum phosphorus level: ≤ 5.5) was achieved.

  Dose period, Week 1, 2, 3, 4, 5, 6, 7, 8.

Study Arms (2)

KHK7791

ACTIVE COMPARATOR

During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.

Drug: KHK7791

Placebo

PLACEBO COMPARATOR

During the dosing period, subjects administer the study drug (KHK7791 or placebo) twice daily just before meals in a double blind. The starting dose of the study drug is 5 mg at a time, and the dose is adjusted in the range of 5, 10, 20, and 30 mg at a time based on the dose adjustment criteria described in the study protocol. Dosage adjustment is performed step by step.

Drug: Placebo

Interventions

KHK7791 DRUG

oral administration

KHK7791

Placebo DRUG

oral administration

Placebo

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has voluntarily provided written informed consent to participate in the study.
• Aged ≥ 20 years (expressed in completed years) at the time of providing informed consent.
• Stable chronic renal failure patients who have undergone hemodialysis 3 times per week for at least 12 weeks until screening examination.
• Dialysis conditions, excluding dry weight, should have been unchanged during the last 2 weeks before screening examination.
• The prescribed drug and dosage regimen should have been unchanged during the last 4 weeks before screening examination.
• Serum phosphorus levels should be in the range of ≥ 3.5 and ≤ 6.0 mg/dL at screening examination.
• If on any vitamin D, calcimimetics regimen, bisphosphonate,calcitonin preparations, selective estrogen receptor modulators or teriparatide preparations then the prescribed drug and dosage regimen should have been unchanged for the last 4 weeks before screening examination.
• Kt/V urea ≥ 1.2 at the most recent test in routine medical practice before screening examination.

You may not qualify if:

• Peritoneal dialysis was performed within 12 weeks before screening examination.
• iPTH \>600 pg/mL (should be based on the most recent value from the patients' medical records, etc. before pre-enrollment)
• Having concurrent or a history of inflammatory bowel disease (IBD) or diarrhea-predominant irritable bowel syndrome
• History of gastrectomy or enterectomy or having undergone gastrointestinal tract surgery within 3 months before screening examination.
• Subjects who used anti RANKL preparations within 6 weeks before screening examination.
• Subjects who used anti-sclerostin antibody preparations within 12 weeks before screening examination.
• Having concurrent severe heart disease or hepatic impairment.
• Developed cerebrovascular disease requiring hospitalization within 6 months before screening examination.
• Uncontrollable hypertension or diabetes.
• Scheduled for living donor kidney transplant, change in the mode of dialysis, home hemodialysis, or change in the dialysis center (relocate to another hospital/clinic) during the study period.
• Any diagnosis of and treatment of malignancy within 5 years before screening examination (excluding basal cell carcinoma or surgically resected intraepithelial carcinoma of uterine cervix).

Sponsors & Collaborators

• Kyowa Kirin Co., Ltd.: lead

Study Sites (1)

Inoue Hospital

Suita, Osaka, Japan

Location

MeSH Terms

Conditions

Hyperphosphatemia

Condition Hierarchy (Ancestors)

Phosphorus Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2021
• First Posted: February 23, 2021
• Study Start: March 15, 2021
• Primary Completion: September 27, 2021
• Study Completion: September 27, 2021
• Last Updated: October 28, 2021

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)